Reckitt Records Impairment Charge For Biofreeze
Reckitt recorded a £152m impairment charge for Biofreeze in 2022 after the topical pain relief brand underperformed in the first half of the year. Despite issues for Biofreeze, Reckitt's Health business as a whole had a strong showing over the 12 months, with sales jumping by 19%.
You may also be interested in...
Reckitt Restructure Seeks To Maximize Dietary Supplement Growth
Reckitt has identified “lots of growth spaces and lots of growth potential” for its vitamins, minerals and supplements business, which it will seek to capitalize on by moving the operation to its OTC-focused Health unit.
People On The Move: Appointments At Orkla, PAGB, Afepadi
A round-up of the latest appointments in Europe's consumer health industry: Orkla Health names BioGaia's Ducellier as its CEO; PAGB makes changes to its board; and Afepadi names Uriach's Gispert as its president.
Germany's Dermapharm Looks To Future With Arkopharma As 2022 Sales Rise
Dermapharm has high hopes for 2023 as its acquisition of Arkopharma means the firm is now the number-one and number-three player respectively in the French and Spanish supplements markets.